Collaborators Work On Bionic Pancreas System

Senseonics Holdings, a med-tech company focused on the development and commercialization of transformative glucose monitoring products, and Beta Bionics, a med-tech leveraging machine learning artificial intelligence to develop and commercialize the first autonomous bionic pancreas, have entered into a development agreement to integrate glucose data from the Eversense Continuous Glucose Monitoring (CGM) system into the iLet Bionic Pancreas system. The Eversense CGM system is a long-term, implantable continuous glucose monitoring system that continually measures interstitial fluid glucose levels and wirelessly sends the readings to a smartphone application. The iLet Bionic Pancreas system is a dual-chamber, autonomous, infusion pump that mimics a biological pancreas by automatically and autonomously adapting insulin and glucagon dosing to meet the individual needs of a person with diabetes.


Under this development agreement, Beta Bionics will work with Senseonics to integrate the Eversense CGM system with the iLet, so that real-time Eversense data may serve as one CGM option to drive the fully autonomous iLet Bionic Pancreas system.

Free Newsletter

Like this article? Subscribe to FierceSensors!

The sensors industry is constantly changing as innovation runs the market’s trends. FierceSensors subscribers rely on our suite of newsletters as their must-read source for the latest news, developments and analysis impacting their world. Register today to get sensors news and updates delivered right to your inbox.


For more insights and better blood-sugar levels, visit Senseonics and Beta Bionics.

Suggested Articles

Machine learning challenge will look for vocal communication between elephants and other behaviors

Iowa State University researchers are working with NSF grant

Brain Corp. reported a sharp increase in autonomous robot usage in 2Q